Both monoclonal antibodies and small tyrosine kinase inhibitors (TKIs) to block/inhibit EGFR’s kinase activity have been developed as targeted therapies for EGFR-dependent cancers [1,2,5]. This evidence concerns the gene EGFR and cancer.